| Development of azithromycin–PLGA nanoparticles: Physicochemical characterization and antibacterial effect against Salmonella typhi G Mohammadi, H Valizadeh, M Barzegar-Jalali, F Lotfipour, K Adibkia, ... Colloids and Surfaces B: Biointerfaces 80 (1), 34-39, 2010 | 181 | 2010 |
| Theranostic MUC-1 aptamer targeted gold coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging and photothermal therapy of colon cancer M Azhdarzadeh, F Atyabi, AA Saei, BS Varnamkhasti, Y Omidi, M Fateh, ... Colloids and Surfaces B: Biointerfaces 143, 224-232, 2016 | 164 | 2016 |
| Protein corona hampers targeting potential of MUC1 aptamer functionalized SN-38 core–shell nanoparticles BS Varnamkhasti, H Hosseinzadeh, M Azhdarzadeh, SY Vafaei, ... International journal of pharmaceutics 494 (1), 430-444, 2015 | 97 | 2015 |
| Nanotoxicology: advances and pitfalls in research methodology M Azhdarzadeh, AA Saei, S Sharifi, MJ Hajipour, AM Alkilany, ... Nanomedicine 10 (18), 2931-2952, 2015 | 94 | 2015 |
| MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery E Sayari, M Dinarvand, M Amini, M Azhdarzadeh, E Mollarazi, Z Ghasemi, ... International journal of pharmaceutics 473 (1-2), 304-315, 2014 | 92 | 2014 |
| Overcoming therapeutic obstacles in inflammatory bowel diseases: a comprehensive review on novel drug delivery strategies F Talaei, F Atyabi, M Azhdarzadeh, R Dinarvand, A Saadatzadeh European Journal of Pharmaceutical Sciences 49 (4), 712-722, 2013 | 92 | 2013 |
| Anti-bacterial performance of azithromycin nanoparticles as colloidal drug delivery system against different gram-negative and gram-positive bacteria M Azhdarzadeh, F Lotfipour, P Zakeri-Milani, G Mohammadi, H Valizadeh Advanced Pharmaceutical Bulletin 2, 2012 | 72 | 2012 |
| Antibacterial activity of clarithromycin loaded PLGA nanoparticles H Valizadeh, G Mohammadi, R Ehyaei, M Milani, M Azhdarzadeh, ... Die Pharmazie-An International Journal of Pharmaceutical Sciences 67 (1), 63-68, 2012 | 53 | 2012 |
| Application of nanostructured lipid carriers: the prolonged protective effects for sesamol in in vitro and in vivo models of ischemic stroke via activation of PI3K signalling … P Hassanzadeh, F Atyabi, R Dinarvand, AR Dehpour, M Azhdarzadeh, ... DARU Journal of Pharmaceutical Sciences 25 (1), 1-16, 2017 | 46 | 2017 |
| Sensing of Alzheimer’s disease and multiple sclerosis using nano-bio interfaces MJ Hajipour, F Ghasemi, H Aghaverdi, M Raoufi, U Linne, F Atyabi, ... Journal of Alzheimer's Disease 59 (4), 1187-1202, 2017 | 44 | 2017 |
| External magnetic fields affect the biological impacts of superparamagnetic iron nanoparticles S Shanehsazzadeh, A Lahooti, MJ Hajipour, M Ghavami, M Azhdarzadeh Colloids and Surfaces B: Biointerfaces 136, 1107-1112, 2015 | 27 | 2015 |
| Serum multivalent cationic pattern: speculation on the efficient approach for detection of Alzheimer's disease M Azhdarzadeh, M Noroozian, H Aghaverdi, SM Akbari, L Baum, ... Scientific reports 3 (1), 1-6, 2013 | 23 | 2013 |
| Interferon beta-1a as a Candidate for COVID-19 Treatment; An Open-Label Single-Arm Clinical Trial P Payandemehr, M Azhdarzadeh, H Bahrami-Motlagh, A Hadadi, ... Advanced Journal of Emergency Medicine 4 (2s), e51-e51, 2020 | 22 | 2020 |
| Is amyloid-β an innocent bystander and marker in Alzheimer's disease? Is the liability of multivalent cation homeostasis and its influence on amyloid-β function the real mechanism? A ManafiRad, F Farzadfar, L Habibi, M Azhdarzadeh, H Aghaverdi, ... Journal of Alzheimer's Disease 42 (1), 69-85, 2014 | 18 | 2014 |
| Core shell methyl methacrylate chitosan nanoparticles: In vitro mucoadhesion and complement activation F TALAEI, M AZHDARZADEH, NH HASHEMI, M MOOSAVI, ... Daru, 2011 | 15 | 2011 |
| A Randomized, Double-blind, Parallel Pharmacokinetic Study Comparing the Trastuzumab Biosimilar Candidate, AryoTrust®, and Reference Trastuzumab in Healthy Subjects M Farmahani Farahani, P Maghzi, N Jafari Aryan, B Payandemehr, ... Expert Opinion on Investigational Drugs, 2020 | 7 | 2020 |
| Amyloid fibril inhibition, acceleration, or fragmentation; Are nano-based approaches advance in the right direction? MJ Hajipour, H Mohammad-Beigi, I Nabipour, N Mahmoudi, ... Nano Today 35, 100983, 2020 | 6 | 2020 |
| A Randomized Pharmacokinetic/Pharmacodynamic Study Comparing The Bioequivalence Of Potential Biosimilar Candidate P044 With Reference Medicine In Healthy Volunteers E Raykova, M Farmahini Farahani, S Ivanova, M Azhdarzadeh Expert Opinion on Biological Therapy, 2021 | 1 | 2021 |
| A randomized pharmacokinetic-pharmacodynamic evaluation of the potential biosimilar interferon beta-1a product, CinnoVex® M Scheinin, Z Lovró, IH Maadik, J Suopanki-Lalowski, SH Seyedagha, ... Expert Opinion on Biological Therapy, 1-10, 2021 | 1 | 2021 |
| Study of anti-microbial effects of Clarithromycin nanosuspensions against Staphylococcus aureus and Salmonella typhi F Lotfipour, H Valizadeh, M Azhdarzadeh, P Zakeri Milani Pharmaceutical Sciences 18 (1), 1-8, 2012 | 1 | 2012 |
Rassoul DinarvandProfessor of Pharmaceutical Nanotechnology, Tehran University of Medical Sciences (TUMS)Verified email at tums.ac.ir
